Portfolio strategists are forecasting a shift into small-cap opportunities next year that will disproportionately benefit high-quality business development companies such as Ares Capital. With private middle-market lending expected to see deal volume rise by an estimated 15% in 2026 as benchmark rates ease, ARCC’s senior secured exposure across more than 300 portfolio companies positions it to capture increased origination fees. The fund currently trades at near net asset value, supports a dividend yield in excess of 10%, and boasts 1.5x coverage of its quarterly payout, giving investors both income stability and potential NAV accretion as market sentiment rotates.

Recent repricing in the floating-rate loan market has narrowed ARCC’s borrowing spreads by roughly 20 basis points since mid-2025, lowering its cost of funds to just above SOFR plus 2.8%. As benchmark rates trend downward, ARCC stands to benefit from wider net interest margins—projected to expand by approximately 30 basis points over the next year—and from spillover income generated by its equity co-investments. Management has indicated that improved funding costs will allow for more competitive origination terms, underpinning anticipated portfolio growth of 5%–7% in the coming 12 months.

Ares Capital announced that it paid four quarterly distributions totaling $1.9200 per share in calendar year 2025. Of that amount, 70.65% was designated ordinary income eligible for the qualified dividend rate under IRC section 854(b), while 29.35% was classified as interest-related dividends under IRC section 871(k). No portion of the distributions was designated as long-term capital gains, and tax advisors note that shareholders should treat the full $1.9200 per share as current income for U.S. federal tax purposes.

Sell-side research firms continue to view ARCC favorably, with more than two-thirds of covering analysts maintaining a buy or overweight recommendation. Consensus estimates call for net investment income to grow by 8% year-over-year in 2026, driven by the expected expansion of deal flow and margin improvements. Additionally, the average target price implied upside of roughly 12% from current levels, reflecting confidence in ARCC’s portfolio diversification—spanning healthcare, technology services and industrial sectors—and its ability to sustain a 10%+ dividend yield even in a moderating rate environment.